Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
Nanobiotix (NASDAQ: NBTX), a clinical biotechnology company focused on cancer treatment, has announced a postponement of its full-year 2022 financial results originally set for March 28, 2023, and its conference call on March 29, 2023. The decision is made to provide additional time for year-end closing procedures. The company will issue a future press release to update stakeholders on the new schedule. Nanobiotix is recognized for its innovative physics-based therapeutic approaches and has developed NBTXR3, which has received market approval in Europe for treating soft tissue sarcoma.
- Nanobiotix is preparing to announce its full-year financial results, suggesting potential updates on performance metrics.
- The company has achieved market authorization in Europe for NBTXR3, demonstrating progress in product development.
- The postponement of financial results adds uncertainty about the company's recent performance.
- Delays in announcing financial outcomes may negatively affect investor confidence.
PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023.
The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures.
About NANOBIOTIX:
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Kate McNeil SVP, Investor Relations +1 (609) 678-7388 investors@nanobiotix.com |
| Media Relations | |
| FR – Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com | Global – LifeSci Advisors Ligia Vela-Reid +44 (0) 7413825310 Lvela-reid@lifesciadvisors.com |
Attachment
FAQ
When will Nanobiotix release its financial results for FY 2022?
What is the significance of the postponement of NBTX's financial results?
What product has Nanobiotix gained market approval for?
What is the stock symbol for Nanobiotix?
